Cargando…
Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine
Lapatinib and capecitabine (L-CAP) is effective in HER-2 positive patients with metastatic breast cancer (MBC). However, moderate to severe diarrhea and rash (≥ grade 2) are problematic dose limiting toxicities. Since risk may vary over the course of therapy, we developed repeated measures models to...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4173070/ https://www.ncbi.nlm.nih.gov/pubmed/25216762 http://dx.doi.org/10.1007/s10549-014-3126-0 |